# AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

> **NCT00275028** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 47 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Primary Peritoneal Serous Adenocarcinoma
- Recurrent Ovarian Epithelial Cancer
- Stage I Ovarian Epithelial Cancer
- Stage II Ovarian Epithelial Cancer

## Interventions

- **DRUG:** cediranib maleate

## Key facts

- **NCT ID:** NCT00275028
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2010-03
- **Final completion:** 2011-01
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2015-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00275028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00275028, "AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00275028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*